recombinant human ace2 protein  (Sino Biological)

Journal: International Journal of Molecular Sciences

Article Title: Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection

doi: 10.3390/ijms26167663

Figure Lengend Snippet: ( A ) Quantification of ACE2, on lungs, by ELISA in uninfected mice treated or not with Losartan or Losartan + Lisinopril combination over 21 days (black and white columns; UU: uninfected untreated; CTU: combination-treated, uninfected; LTU: Losartan-treated, uninfected) and in the same animals after infection with SARS-CoV-2 (colored columns; CTI [gray]: combination-treated, infected; LTI [green]: Losartan-treated, infected; UI [red]: untreated, infected). ( B ) Viral load in SARS-CoV-2-infected K18-hACE2 mice treated or not with Losartan or Losartan-Lisinopril combination on days 3, 5, or 6/7 post-infection. (*) Significant difference between groups: * p < 0.05, ** p < 0.005, **** p < 0.0001. The normality of the data was assessed using the Shapiro–Wilk test. A one-way ANOVA was performed, followed by the Bonferroni post-test (A-Treated non-infected), and mixed-effects analyses were conducted, followed by the Tukey post-test (A-Treated infected/B). (*) Significant difference between specific groups as indicated by the lines: * p < 0.05, ** p < 0.005, **** p < 0.0001. Data are presented as mean ± SEM. n = 10 per time point.

Article Snippet: Detection and quantification of ACE2 protein in tissue samples were performed using the Human ACE2 DuoSet ELISA kit (R&D Systems- Cat. DY933-05, Minnneapolis, MN, USA), following the manufacturer’s recommendations.

Techniques: Enzyme-linked Immunosorbent Assay, Infection